Ausilium Bau 100G

AUSILIUM BAU

Powder supplement for dogs that helps protect the urinary tract.
Indicated as a complementary remedy in cystitis and other urinary tract infections, it is particularly effective against Escherichia coli, Klebsiella, Enterococcus faecalis, Streptococcus, Staphylococcus, Proteus, Pseudomonas, and other fimbrial bacteria. Unlike antibiotic therapy, bacteria are not killed but removed mechanically, dragged outside with the urine flow. This allows to avoid damaging the physiological bacterial flora, a valuable ally for the animal's health.
AUSILIUM MIAO can be taken both during acute phases (in combination with specific therapies indicated by the veterinarian) and in recurrent or relapsing forms (alone or in combination with diets recommended by the veterinarian). Additionally, it can also be used for prevention and maintenance phases.

Ingredients
Maltodextrin, Pork liver flour, D-Mannose.
Botanically defined natural products: Morinda citrifolia L. extract 70,000 mg.

Usage instructions
Mix the powder with the usual wet food ration according to the following daily dosage:
- up to 10 kg of weight: 2 scoops per day, in two administrations, for a total of 3 g;
- from 10 to 20 kg of weight: 4 scoops per day, in two administrations, for a total of 6 g;
- over 20 kg of weight: 6 scoops per day, in two administrations, for a total of 9 g.
During prevention and maintenance phases, half the dosage will be sufficient.
If feeding is exclusively dry, lightly moisten the food to ensure good adhesion of the powder and its complete ingestion.
It is advisable to perform a 10-15 day administration cycle, optionally repeatable at the veterinarian's discretion.

Warnings
For veterinary use only. Keep out of reach of children.

Storage
Store in a dry place away from light.

Format
Pack of 100 g.

Code PT267

Bibliography:
1. Abgottspon D, Rabbani S, Herold J, Jiang X, Ernst B. FimH antagonists for the oral treatment of urinary tract infection: from design and synthesis to in vitro and in vivo evaluation. Klein J Med Chem Dec 2010;53:8627-41.
2. Akihisa T, Matsumoto K, Tokuda H. Anti-inflammatory and potential cancer chemopreventive constituents of the fruits of Morinda citrifolia (Noni). J Nat Prod 2007;70:754-7.
3. Alitheen NB, Manaf AA, Yeap SK. Immunomodulatory effects of Damnacanthal isolated from roots of Morinda elliptica. Pharm Biol 2010;48:446-52.
4. Altarac S, Papes D. Use of d-mannose in prophylaxis of recurrent urinary tract infections (UTIs) in women. BJU Int 2014;113:9-10.
5. American Chemical Society. Noni plant may yield new drugs to fight tuberculosis. Press Release at the 2000 International Chemical Congress of Pacific Basin Societies.
6. Crepin S, Houle S, Carbanneau ME', Mourez M, Harel J, Dozois CM. Decreased expression of type 1 fimbriae by a pst mutant of uropathogenic Escherichia coli in urinary tract infection: contribution to intracellular biofilm development. Virulence 2010;1:333-7.
7. Cusumano CK, Pinkner JS, Han Z, Handerson JP, Croweley JR, Hultgren SJ. Treatment and prevention of urinary tract infection with orally active FimH inhibitors. Sci Transl Med Nov 2011;3:109-15.
8. Gupta RK, Banerjee A, Pathak S. Induction of mitochondrial-mediated apoptosis by Morinda citrifolia (Noni) in human cervical cancer cells. Asian Pac J Cancer Prev 2013;14:237-42.
9. Gupta RK, Patel AK. Do the health claims made for Morinda citrifolia (Noni) harmonize with current scientific knowledge and evaluation of its biological effects. Asian Pac J Canc Prev 2013;14:147-49.
10. Heinicke R. The Xeronine system: a new cellular mechanism that explains the health promoting action of NONI and Bromelina. Direct Source Pub 2001.
11. Jiang X, Abgottspon D, Kleeb S, Rabbani S, Scharenberg M, Wittwer M et al. Antiadhesion therapy for urinary tract infections--a balanced PK/PD profile proved to be key for success. J Med Chem 2012;55:4700-13.
12. Kranjcec B, Papes D, Altarac S. D-mannose powder for prophylaxis of recurrent urinary tract infections in women: a randomized clinical trial. World J Urol 2013;32:79-84.
13. Nava CM, Ricciardo G, Valieri M. Treatment and prevention of recurrent vaginitis. Medicinae Doctor 2013 issue 8.
14. Pawlus AD, Su BN, Keller WJ. An anthraquinone with potent quinone reductase-inducing activity and other constituents of Morinda citrifolia (Noni) fruits. J Nat Prod 2005;68:1720-2.
15. Porru D, Parmigiani A, Tinelli C, Barletta D, Choussos D, Di Franco C, Bobbi V, Bassi S, Miller O, Gardella B, Nappi RE, Spinillo A and Rovereto B. Oral D-mannose in recurrent urinary tract infections in women: a pilot study. J Clin Urol 2014; 20 (10): 1–6.
16. Pratt LA, Kolter R. Genetic analysis of Escherichia coli biofilm formation: roles of flagellar motility, chemotaxis and type 1 pili. Mol Microbiol 1998;30:285-93.
17. Reid G, Sobel JD. Bacterial adherence in the pathogenesis of urinary tract infection: a review. Clin Infect Dis 1987;9:470-87.
18. Sharon N. Carbohydrates as future anti-adhesion drugs for infectious diseases. Biochim Biophys Acta 2006;1760:527-37.
19. Umezawa K. Isolation of 1-methoxy-2-foremyl3-hydroxyanthraquinone from M citrifolia and neoplasminhibitors containing the same. Japan Kokai Tokyo Koho JP 1992;87:736(94-87, 736).
20. Wellens A, Garofalo C, Nguyen H, Van Gerven N, Bouckaert J. Intervening with urinary tract infections using anti-adhesives based on crystal structure of the FimH-ologomannose-3 complex. PLoS one 2008;3:e2040.